ArticleScientific reports2026
Identification of altered salivary microRNAs in Cavalier King Charles Spaniels affected by mitral valve disease at different ACVIM stages.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Myxomatous mitral valve disease (MMVD) in Cavalier King Charles Spaniels (CKCSs) can be diagnosed at a young age. Early and sensitive biomarkers related to the disease are currently lacking. MicroRNAs (miRNAs) are involved in the onset and progression of canine MMVD. This study aimed to profile the salivary miRNAs associated with MMVD severity in CKCSs and to identify their target genes. This was a pilot prospective, cross-sectional study. Saliva was collected from twenty-five CKCSs belonging to the American College of Veterinary Internal Medicine (ACVIM) stages A (n. 6), B1 (n. 13), and B2 (n. 6), and salivary miRNAs’ expression was profiled by Next Generation Sequencing. miRNAs’ target genes were identified using bioinformatic tools. Results showed that 25 miRNAs were differentially expressed (DE) between ACVIM A and B1 dogs; 35 DE-miRNAs were modulated in ACVIM B2 compared to B1 CKCSs; 4 miRNAs were up-regulated in ACVIM stage B1 patients compared to both ACVIM stages A and B2. These findings confirm that salivary miRNAs can be successfully quantified in CKCSs and that their expression differs across MMVD severity groups. The DE-miRNAs were associated with signalling pathways related to cellular metabolism, survival, and early inflammatory remodeling. Given the exploratory and cross-sectional design, these miRNAs should be considered candidate, non-invasive indicators associated with disease severity rather than established biomarkers. Further longitudinal and validation studies are needed to assess their diagnostic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.